Fetal toxic effects of angiotensin II receptor antagonists: Case report and follow-up after birth

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 157-161

  Bos Thompson, Marie Andrée ^a   Hillaire Buys, Dominique ^a   Muller, Françoise ^b   Dechaud, Hervé ^c   Mazurier, Evelyne ^c   Boulot, Pierre ^c   Morin, Denis ^c  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Child renal insufficiency; Pregnancy; Valsartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA 2 MICROGLOBULIN; HYDROCHLOROTHIAZIDE; LEVOTHYROXINE; LYSINE ACETYLSALICYLATE; PRAZOSIN; VALSARTAN;

ANHYDRAMNIOS; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; FETUS DISEASE; GROWTH; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; NEPHROTOXICITY; NEWBORN; PREGNANCY; PREGNANCY TERMINATION; PRIORITY JOURNAL;

AMNIOTIC FLUID; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BETA 2-MICROGLOBULIN; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; HYPERTENSION; INFANT; INFANT, NEWBORN; KIDNEY FAILURE; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL EXPOSURE DELAYED EFFECTS; TETRAZOLES; VALINE;

EID: 11144223017     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E250     Document Type: Article

References (16)

1. Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects (letter). Lancet 2001;357:63.
2. Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001;358:241-2.
3. Lambot MA, Vermeylen D, Noel JC. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1619-20.
4. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmacother 2001;35:859-61. DOI 10.1345/aph.1A013
5. Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin-II-receptor antagonists in pregnancy. Br J Obstet Gynaecol 2003;110:1038-40.
6. Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morvillle P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol 2003;23:254-5.
7. Hinsberger A, Wingen AM, Hoyer PF. Angiotensin-II-receptor inhibitors in pregnancy (letter). Lancet 2001;357:1620.
8. 2-microglobulin predicts postnatal renal function in bilateral uropathies. Kidney Int 2000;58:312-6.
9. Apgar V. Proposal for a new method of evaluation of the new born infant. Curr Anesth Anal 1953;32:260-7.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Spence SG, Allen HL, Cukierski MA. Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995;51:367-82.
12. Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1620-1.
13. Lip GYH, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting enzyme inhibitors in early pregnancy. Lancet 1997;350:1446-7.
14. Steffenssen FH, Nielsen GL, Sorensen TH, Olesen C, Olsen J. Pregnancy outcome with ACE-inhibitor use in early pregnancy (letter). Lancet 1998;351:596.
15. Schaefer C. Angiotensin II receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res Part A. Clin Mol Teratol 2003;67:591-4.
16. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res Part A 2004;70:547-9.